Impact Factor 4.416

Frontiers journals are at the top of citation and impact metrics

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2018.00379

Hypofractionated radiation therapy treatment in the management of patients with large brain metastases

  • 1Centre Hospitalier de l’Université de Montréal, Canada

Single fraction radiosurgery (SRS) treatment is an effective and recognized alternative to whole brain radiation for brain metastasis. However, SRS is not always possible, especially in tumours of a larger diameter where the administration of high dose in a single fraction is limited by the possibility of acute and late side effects and the dose to the surrounding organs at risk. Hypofractionated radiation therapy allows the delivery of high doses of radiation per fraction while minimizing adverse events, all the while maintaining good local control of lesions. The optimal dose fractionation has however not been established. This overwiew presents available evidence and rationale supporting usage of hypofractionated radiation therapy in the treatment of large brain metastases.

Keywords: large brain metatasis, Hypofractionation, Hypofractionated radiosurgery, Stereotactic radiosurgery, multi-stage radiosurgery

Received: 02 Jun 2018; Accepted: 23 Aug 2018.

Edited by:

Arjun Sahgal, University of Toronto, Canada

Reviewed by:

David M. Peereboom, Cleveland Clinic Lerner College of Medicine, United States
Riccardo Soffietti, Università degli Studi di Torino, Italy  

Copyright: © 2018 Laura. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Masucci Laura, Centre Hospitalier de l’Université de Montréal, Montreal, Canada,